Mangalam Global Enterprise Limited has secured in-principle approval from major Indian stock exchanges for listing equity shares under its employee stock option scheme. The company announced that it has received approvals from both National Stock Exchange of India Limited and BSE Limited for its Employee Stock Option Plan 2026.

Stock Exchange Approvals

The approvals cover the listing of up to 33,00,000 equity shares of Rs. 1/- each to be issued under the Employee Stock Option Plan 2026. Both exchanges granted their approvals under Regulation 28(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Formal Documentation and Communication

The company issued formal communications to both exchanges under reference number MGEL/CS/SE/2026-27/11. Company Secretary Karansingh I. Karki (Mem. No. A30021) signed the official notifications pursuant to Regulation 30 of the SEBI Listing Regulations, confirming receipt of the in-principle approvals.

Compliance Conditions

The in-principle approvals are subject to several mandatory compliance conditions that the company must fulfill. These conditions ensure adherence to regulatory frameworks and protect investor interests.

Key Requirements Include:

• Notification to exchanges as per Regulation 10(c) format after share allotment and crediting to beneficiaries' accounts
• Payment of prescribed fees as determined by the exchanges
• Receipt of all statutory and regulatory approvals from authorities including SEBI, RBI, and MCA
• Compliance with exchange guidelines, regulations, and directions
• Adherence to SEBI LODR Regulations 2015 conditions
• Compliance with Companies Act provisions and other applicable laws

Regulatory Framework

The Employee Stock Option Plan 2026 operates under the Securities Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company submitted the required statement under Regulation 10(b) along with other necessary documentation to both exchanges.

Exchange Reservations and Final Approval Process

Both NSE and BSE have reserved the right to withdraw their in-principle approvals if any submitted information is found to be incomplete, incorrect, misleading, or false. The exchanges also retain the right to revoke approval for any contravention of rules, bye-laws, regulations, listing agreements, or statutory guidelines.

The exchanges will issue final trading permissions upon receipt of notification under Regulation 10(c) and subject to compliance with all stated conditions. Additional documentation requirements include certified copies of board resolutions, allottee lists, and confirmation from registrar and transfer agents regarding share credit or certificate dispatch.

Mangalam Global Enterprise Limited has announced strong financial results for Q4FY26, following the board meeting held on April 18, 2026. The company reported significant growth in both revenue and profitability, with total income reaching ₹1,065.27 crores and profit after tax surging 140% year-on-year.

Financial Performance Highlights

The company's financial results demonstrate robust operational performance across key metrics:

Board Meeting Outcomes

The board of directors successfully concluded their scheduled meeting on April 18, 2026, where they considered and approved the audited financial results. The meeting agenda covered several critical business matters:

Regulatory Compliance and Trading Window

The company maintained strict adherence to regulatory requirements throughout the results announcement process. The trading window for dealing in equity shares was closed from April 01, 2026, and remained restricted until 48 hours after the financial results declaration, ensuring compliance with insider trading regulations.

The results announcement represents the culmination of the company's planned disclosure process, with the board meeting notification having been communicated to both NSE and BSE on April 15, 2026. Company secretary and compliance officer Karansingh I. Karki oversaw the regulatory documentation and adherence procedures.